Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.
Wan, H., Schroeder, G.M., Hart, A.C., Inghrim, J., Grebinski, J., Tokarski, J.S., Lorenzi, M.V., You, D., Mcdevitt, T., Penhallow, B., Vuppugalla, R., Zhang, Y., Gu, X., Iyer, R., Lombardo, L.J., Trainor, G.L., Ruepp, S., Lippy, J., Blat, Y., Sack, J.S., Khan, J.A., Stefanski, K., Sleczka, B., Mathur, A., Sun, J.H., Wong, M.K., Wu, D.R., Li, P., Gupta, A., Arunachalam, P.N., Pragalathan, B., Narayanan, S., K C, N., Kuppusamy, P., Purandare, A.V.(2015) ACS Med Chem Lett 6: 850-855
- PubMed: 26288683 
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00226
- Primary Citation of Related Structures:  
5CF8 - PubMed Abstract: 
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway. X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole 1 led to the discovery of a clinical candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.
Organizational Affiliation: 
Bristol-Myers Squibb R&D , US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States.